Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.

ABSTRACT:

Introduction

Copeptin is the stable surrogate marker of vasopressin (VP), which is released in response to elevated plasma osmolality or low blood pressure. Elevated plasma copeptin levels are associated with higher risk of insulin resistance-related disorders, such as type 2 diabetes (T2DM), metabolic syndrome (MS), and cardiovascular disease, and experimental reduction of circulating VP levels is shown to significantly decrease hepatic fat content in obese rats, independently from body adiposity. However, the association between copeptin and non-alcoholic fatty liver disease and steatohepatitis (NAFLD/NASH) in humans has not been explored yet. The aim of this study was to explore the relationship between plasma copeptin and the presence/severity of NAFLD/NASH.

Methods

For

SUBMITTER: Barchetta I 

PROVIDER: S-EPMC6489227 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature